GeneFerm Biotechnology Co Ltd

GeneFerm Biotechnology Co Ltd

1796 · TWO · Healthcare / Drug Manufacturers - Specialty & Generic

28.50TWD+0.90 (+3.26%)

Price History

Full chart

Market Stats

Previous Close27.60
Open28.50
Day Range28.50 – 28.50
52-Week Range28.25 – 56.00
Volume1.27K
Market Cap1.26B
P/E (TTM)73.90
Forward P/E0.00
EPS0.41
Dividend Yield2.40%
Beta0.07
50-Day Avg29.98
200-Day Avg37.24

About

GeneFerm Biotechnology Co., Ltd. develops, manufactures, and sells fermented health products in Taiwan and internationally. The company provides microbial fermentation products, including fungi, bacteria, lactic acid bacteria, yeast, algae, etc.; bio fermented ingredients, such as nattomena, natto fermented powder, red yeast rice fermented powder, antrodia cinnamomea mycelia powder, cordyceps, reishi mycelia, phellinus linteus mycelia powder, armillaria mellea mycelia powder, beta-glucan powder, and fruits and vegetables fermented enzyme, as well as probiotics and peptide ingredients. It also provides private label supplements; and microbial fermentation toll manufacturing services. The company was founded in 1999 and is headquartered in Tainan City, Taiwan.

Company Details

  • SectorHealthcare
  • IndustryDrug Manufacturers - Specialty & Generic
  • CEOJinde Jin
  • Employees0
  • HeadquartersNo.3, Dali 2nd Rd., Tainan City, Taiwan, 741014, Taiwan
  • Websitehttps://www.geneferm.com

Leadership

  • Jinde JinManager
  • Qimian SuAccounting Supervisor

Financials

Income Statement

Currency: TWD2017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue349.83M357.45M328.23M368.30M522.33M633.96M793.77M521.16M677.10M
Growth (%)-+2.18%-8.17%+12.21%+41.82%+21.37%+25.21%-34.34%+29.92%
Cost of Revenue201.89M239.53M250.70M246.32M329.68M411.80M507.42M424.42M486.30M
Gross Profit147.94M117.92M77.53M121.98M192.65M222.16M286.35M96.75M190.80M
Gross Margin42.29%32.99%23.62%33.12%36.88%35.04%36.07%18.56%28.18%
Operating Expense111.75M108.10M100.91M104.46M113.50M108.85M129.17M132.24M144.76M
Operating Income36.19M9.82M-23.38M17.52M79.15M113.31M157.18M-35.49M46.04M
Operating Margin10.35%2.75%-7.12%4.76%15.15%17.87%19.80%-6.81%6.80%
EBITDA64.86M45.94M14.43M58.59M124.51M163.34M230.67M56.34M115.40M
EBITDA Margin18.54%12.85%4.40%15.91%23.84%25.77%29.06%10.81%17.04%
Net Income28.23M10.31M-27.55M4.53M57.41M93.45M124.62M-22.53M28.86M
Net Income Margin8.07%2.89%-8.39%1.23%10.99%14.74%15.70%-4.32%4.26%
R&D23.25M25.15M22.14M22.41M23.56M24.18M28.33M29.31M33.54M
R&D as % of Total Revenue6.64%7.03%6.74%6.08%4.51%3.81%3.57%5.62%4.95%
Interest Expense01.43M9.76M9.82M7.32M3.82M4.17M4.44M6.22M
Interest Expense % of Total Revenue0.00%0.40%2.97%2.67%1.40%0.60%0.53%0.85%0.92%

Balance Sheet

Currency: TWD2017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets508.75M557.20M1.00B982.58M1.32B1.19B1.18B1.15B1.28B
Total Liabilities193.79M140.69M46.00M586.38M569.22M358.86M282.54M358.31M464.00M
Total Equity314.95M416.51M389.72M396.19M747.66M830.77M892.84M788.18M816.66M
Cash67.56M110.38M21.69M348.02M539.61M100.69M120.15M122.45M280.26M
Total Debt--550.61M511.67M464.70M219.16M152.08M--
Net Debt65.44M-528.92M163.65M-74.91M118.47M31.93M39.78M-

Cash Flow

Currency: TWD2017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow61.08M42.14M14.69M56.42M112.23M122.43M190.31M8.09M99.31M
Investing Cash Flow-56.16M-29.59M-54.86M-82.04M-145.25M-280.33M---
Financing Cash Flow-906.00K31.01M356.86M-53.06M224.81M-281.79M-99.87M--
Capital Expenditure55.16M28.81M54.57M82.32M145.61M278.42M71.40M22.70M23.42M
Free Cash Flow5.02M12.78M-39.89M-25.90M-33.37M-155.98M118.91M-14.61M75.89M
Dividends Paid52.41M27.44M13.90M3.39M3.39M41.46M62.19M82.92M-
FCF to OCF8.22%30.34%-271.57%-45.91%-29.74%-127.40%62.48%-180.57%76.42%
Dividend Paid to FCF1044.19%214.64%-34.85%-13.08%-10.15%-26.58%52.30%-567.63%-

Earnings

Report DateMar 31, 2017Jun 30, 2017Nov 29, 2017Feb 28, 2018May 30, 2018Aug 29, 2018Nov 28, 2018Feb 27, 2019May 29, 2019Aug 28, 2019Nov 27, 2019Feb 26, 2020Jun 3, 2020Sep 2, 2020Dec 2, 2020Mar 3, 2021Jun 2, 2021Sep 1, 2021Dec 1, 2021Mar 2, 2022Jun 1, 2022Aug 31, 2022Nov 30, 2022Mar 1, 2023May 31, 2023
EPS Estimate-------------------------
EPS Actual0.160.480.350.100.020.090.050.20-0.17-0.31-0.08-0.42-0.200.000.150.220.300.240.400.390.460.720.610.420.73
Surprise-------------------------
Timing-------------------------

Key Statistics & Ratios

Market Cap1.26B
Enterprise Value1.27B
Trailing P/E73.90
Forward P/E0.00
Price / Sales1.89
Price / Book1.59
EPS0.41
Book Value18.91
Revenue (TTM)664.93M
Gross Profit (TTM)170.94M
EBITDA85.71M
Profit Margin2.57%
Operating Margin1.16%
Return on Equity2.16%
Return on Assets0.98%
Shares Outstanding41.46M
Shares Float20.67M
Beta0.07
Dividend Yield2.40%
Dividend Rate0.70
Payout Ratio0.00%

Dividends

20261×
0.70Jul 14, 2026
20241×
2.00Jul 10, 2024
20231×
1.50Jun 29, 2023
20221×
1.00Jun 23, 2022
20211×
0.08Jul 22, 2021
20191×
0.50Jul 18, 2019
20181×
1.00Jul 3, 2018
20171×
2.10Jul 18, 2017